Furthermore, thalidomide improves the severity and frequency of bleeding from nasal telangiectasias in HHT patients, which is likely through the promotion of vessel maturation due to an upregulation of platelet-derived growth factor-B (PDGF-B) expression [28, 29]. The gene discussed is PDGFB; the disease is hereditary hemorrhagic telangiectasia.